Lerkanidipin Actavis

Lercanidipine, the active ingredient in Lerkanidipin Actavis, is a calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension. GNH USA supplies Lerkanidipin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lerkanidipin Actavis is a calcium channel blocker used in the management of high blood pressure. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications in adults.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Tachycardia or palpitations. - Gastrointestinal discomfort such as nausea.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction or acute coronary syndrome. - Hepatic enzyme elevation or liver injury. - Severe allergic reactions including rash or bronchospasm. - Cardiac arrhythmias requiring medical attention.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: check regularly to ensure therapeutic response. - Hepatic function: assess liver enzymes in patients with known liver disease. - Elderly patients: start at the lowest dose and monitor for orthostatic effects. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - Discontinuation: do not stop abruptly without medical guidance. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Grapefruit juice: can markedly raise drug concentration. - Other calcium channel blockers: additive vasodilatory effect leading to hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure lowering effect. - ACE inhibitors or ARBs: combined therapy may require dose adjustments. - Beta‑blockers: monitor for bradycardia or excessive blood‑pressure reduction. - NSAIDs: may blunt antihypertensive response. - Simvastatin: increased risk of statin‑related muscle toxicity.